

A Simple and Rapid HPLC Method for Assay of Salbutamol, Ciprofloxacin, and Mannitol in a Triple Combination Dry Powder Formulation

Sunita Sule^{1,*}, Sudesh Prabhakar Bhure², Ameet Sule³, Sushama Raju Ambadekar¹

¹Department of Chemistry, Institute of Science, Madam Cama Road, Fort, Mumbai, India

²Independent Consultant, India

³H&T Presspart, UK

Abstract A simple, rapid, and novel high-performance liquid chromatography method has been developed and validated for simultaneous estimation of Salbutamol and Ciprofloxacin and Mannitol in a dry powder formulation for inhalation. The chromatographic separation was achieved using a Shodex NH2P-50 4D column and mobile phase composition of Buffer: Acetonitrile (20:80). The detection for Salbutamol and Ciprofloxacin was carried out in a UV detector at 225 nm, and Mannitol was detected in Refractive Index Detector. The method was validated in line with ICH guidelines and was found to be specific, linear, precise, accurate and robust. The % recovery was between 90-110 % for the assay, and the co-eff of linearity was greater than 0.990 for Salbutamol, Ciprofloxacin, and Mannitol. The % RSD for Inter-day and Intra-day Precision was less than 2%. This method will be useful in the assay of the novel combination product.

Keywords Salbutamol, Ciprofloxacin, Mannitol, Validation, ICH guidelines

1. Introduction

Salbutamol Sulphate is a beta-2 adrenergic receptor agonist. It provides rapid and short-acting bronchodilation in reversible airway obstruction. It is used to treat bronchospasm caused by Asthma, COPD, and other lung diseases. In the respiratory tract, its effect is in the form of bronchial smooth muscle relaxation [1]. Ciprofloxacin belongs to the class of drugs called fluoroquinolone antibiotics. It is used to treat several bacterial infections, e.g., respiratory tract infections and urinary tract infections, among others. Its mode of action is by inhibiting enzymes topoisomerase II and topoisomerase IV required for bacterial DNA replication [2]. Mannitol is a naturally occurring sugar that helps rehydrate mucus and airway clearances due to its osmotic properties [3]. The three drugs given in sequence are possible therapy routes in case of lung infections. [4]. The product under study is a novel dry powder for inhalation developed as a combination consisting of 0.2 mg Salbutamol (as Sulphate), 32.5 mg Ciprofloxacin (as Hydrochloride monohydrate) and 80 mg Mannitol via oral inhalation.

Several analytical methods are available for the determination of Salbutamol Sulphate drug and drug product

[5-9], Ciprofloxacin HCL and its drug products [10-14], Mannitol and its impurities [15-17]. However, none are reported for a combination drug product consisting of Salbutamol, Ciprofloxacin, and Mannitol. This paper focuses on developing a novel HPLC method for the simultaneous estimation of Salbutamol, Ciprofloxacin, and Mannitol in the combination product. The current study aimed to develop a simple, isocratic HPLC method with a suitable run time of less than 15 mins. The validation would be conducted in line with the current ICH guidelines.

2. Materials and Methods

Reagents and chemicals

Acetonitrile HPLC-grade Finar, Phosphoric acid AR grade were procured from Finar (India). Triethylamine AR grade was purchased from Emparta (India).

Instrumentation

A High-Performance Liquid Chromatographic Shimadzu LC 20A system, equipped with an autosampler SIL 10 AC HT, column oven CTD-10AS VP, a UV detector SPD 20 A and a RID detector RID 20A was used for the analysis. The data was recorded using Lab Solutions software.

Preparation of Mobile Phase

Mobile phase: Buffer: ACN, 20:80

Prepare a 0.15% orthophosphoric acid solution and adjust the pH to 7 with Triethylamine.

* Corresponding author:

sunitasule.ipc@gmail.com (Sunita Sule)

Received: Aug. 20, 2023; Accepted: Aug. 29, 2023; Published: Aug. 31, 2023

Published online at <http://journal.sapub.org/chemistry>

Preparation of standard solution.

Standard stock solution – A: About 12 mg of Salbutamol sulphate, about 469 mg of Ciprofloxacin Hydrochloride and about 1000 mg of mannitol were weighed in a 50 ml flask and dissolved in 30 ml water diluent by sonication and made up to the mark. (Stock Solution)

Standard Solution - Assay: 5.0 ml of stock solution was transferred to a 10 ml volumetric flask was made up to the mark to give a solution containing 100 µl/ml of Salbutamol, 4000 µl/ml of Ciprofloxacin and 10000 µl/ml of mannitol.

Preparation of Sample solution

Sample solution 1: About 590 mg of sample blend of the novel DPI formulation was transferred in a 10 ml volumetric flask, dissolved, and diluted up to the mark to give a solution containing 100 µg/ml of Salbutamol, 16250 ppm Ciprofloxacin and 40,000 ppm of Mannitol.

Sample Solution 2: 5 ml of the above solution was transferred in a 20 ml volumetric flask and diluted up to mark to give 4062.5 µl/ml solution of Ciprofloxacin and 10,000 µl/ml solution of Mannitol.

Chromatographic condition

Column	: Shodex Asahipak NH2P-50 4D, 150mm x 4.6 mm x 5 micron.
Mobile Phase	: Acetonitrile: Buffer; 80:20
Buffer	: 0.15% orthophosphoric acid solution in water, pH adjusted to 7.0 with Triethylamine
Diluent	: Water
Flowrate	: 1.5 ml/min
Detector 1	: UV detector, Wavelength 225 nm.
Detector 2	: RID detector
RID Detector temp.:	30 °C
Column temp.	: 30 °C
Elution mode	: Isocratic
Software	: Lab solutions

Method Validation

The method was validated in line with the ICH guideline [20-21] for the test of assay, demonstrating the method is suitable for the intended use. Due to the high difference between the concentration of Salbutamol and Ciprofloxacin, the sample solution had to be prepared in two dilutions. The first dilution was used to estimate Salbutamol (100 ppm), and the second dilution was done to estimate Ciprofloxacin (4000 ppm) and Mannitol (10000 ppm).

Specificity

The specificity was performed by injecting solutions of individual Salbutamol sulphate, Ciprofloxacin HCl, Mannitol, and their mixed solution.

Linearity

Linearity test for the assay was performed on five concentration levels between 80 and 120% of the test concentration. Three replicates were injected for 80%, 90%, 100%, 110% and 120% concentration levels.

Accuracy

As there is no excipient in the formulation, the sample accuracy of the assay method was evaluated by determining the % recovery of Salbutamol. Ciprofloxacin and Mannitol at 80%, 100% and 120% of the test concentration.

Precision

System precision was performed by injecting and analyzing five replicate injections of Salbutamol, Ciprofloxacin, and Mannitol standard solution at the test concentration of Assay preparation. Method precision was performed by analyzing six individual sample preparation at 100% of the test concentration level of the Assay preparation. Intermediate precision was performed by testing six individual samples at 100% of the test concentration of Assay preparation on another day.

Robustness

The robustness of the proposed method was determined by studying the effect of small, deliberate changes in temperature ($\pm 2^\circ\text{C}$) and change in pH (± 0.2) on the assay of the formulation.

3. Results and Discussion**Method Optimization**

Development studies were carried out by evaluating parameters influencing separation in chromatography. Salbutamol and Ciprofloxacin are ionic molecules, and Mannitol is a polar compound with no chromophore, thus not suitable for UV detection. The literature search revealed several RP HPLC methods for determining Salbutamol [4-8] and Ciprofloxacin [9-13] individually or with other drug substances using the C8 column and C18. Similarly, there are several methods for determining Mannitol, most of them using RI detector [15-19].

Initially, HPLC column configurations such as C8 And C18 columns with 3-micron and 5-micron size particles in combination with a USP L19 column (to retain mannitol) in series were evaluated. The limitation was that the mobile phase could only consist of water and acetonitrile; a separation was achieved with the C18 and L19 columns in series. At lower concentration, separation of Salbutamol and Ciprofloxacin was achieved probably due to interactions with the stationary phase and that of Mannitol by ion exchange mechanism. However, due to the high concentration of Ciprofloxacin in the sample, the Salbutamol peak merged into the Ciprofloxacin peak. Further, the limitation of not being able to use a buffer for ionic molecules was an issue for getting good peak shape and repeatability for Salbutamol and Ciprofloxacin. In addition, there was a risk that the high concentration of the drugs would be detrimental to the L19 column packing.

The target was to arrive at a column configuration that could support the buffered mobile required for the ionic Salbutamol and Ciprofloxacin as well as separate polar

Mannitol. An alternate approach was to evaluate a Hydrophilic interaction liquid chromatography (HILIC) separation mode. HILIC mode consists of a polar stationary phase and a mobile phase consisting of a high percentage of the organic phase and a low percentage of the aqueous phase. A systematic approach on HILIC column configuration with a range of pH was evaluated, and the best separation was achieved with Shodex Asahipak NH2P – 50 4D column a 0.15% solution of Orthophosphoric acid with pH adjusted to 7 with triethyl amine. The stationary phase consists of spherical porous particles of polyvinyl alcohol modified with an amino group. Due to its polymer base, there would be reduced tailing due to no silanol activity [22]. Salbutamol and Ciprofloxacin are separated by anion exchange and HILIC mechanism and sugars by HILIC mechanism. To ensure salbutamol detection, which had a very low

concentration, Vs Ciprofloxacin and mannitol sample solution was prepared as two dilutions, first for Salbutamol at 100 ppm and second for Ciprofloxacin at 4000 ppm and Mannitol 10000 ppm.

To ensure the complete dissolution of the sample, the diluent selected was water which was different than the mobile phase and gave negative peaks in the RI detector at Ciprofloxacin retention time; hence Salbutamol and Ciprofloxacin were detected on the UV detector and Mannitol on the RID detector. The method was finalized after proper selection and optimization of the pH, sample solution concentration and ratio of Buffer and Acetonitrile. Separation was achieved for Salbutamol, Ciprofloxacin, and Mannitol in an isocratic mode and a run time of less than 15 mins Fig. 1 and 2.

Table 1. Validation Summary

Validation Parameter	limit	Salbutamol	Ciprofloxacin	Mannitol
Specificity				
Retention time	Mins.	5.75	3.12	8.03
System Suitability				
Resolution	NLT 1.5	5.6	-	-
Tailing Factor	< 2	1.18	1.50	1.08
Theoretical Plates	NLT 1000	1592	1215	4306
% RSD	NMT 2.0%	0.26	0.12	0.23
Standard recovery (data for 15 hrs.)	NLT 2.0%	0.24	0.19	0.36
Linearity				
Linearity range	ppm	80 – 120	3200 – 4800	8000 – 12000
Coeff. Correlation r²	NLT 0.990	0.992	0.998	0.999
Precision				
Precision: Mean Assay	90-110%	104.1	94.2	103.4
Precision: % RSD n=6	< 5.0%	0.28	0.29	0.34
Int. Precision: Mean Assay	90-110%	105.6	93.3	103.1
Int. Precision: % RSD n=6	< 5.0%	0.14	0.48	0.26
Precision + Int precision: % RSD n=12	< 5%	0.74	0.55	0.33
Accuracy				
80 %	% Recovery	108.1	91.5	99.7
	% RSD	0.13	0.33	0.07
100 %	% Recovery	107.3	105.4	102.1
	% RSD	0.45	0.70	0.82
120 %	% Recovery	106.9	106.8	101.7
	% RSD	0.33	0.11	0.37
Robustness				
Control	% Assay	105.6	93.3	103.4
pH 6.8	% Assay	105.7	94.9	102.4
pH 7.2	% Assay	104.9	91.7	102.0
Temp. 28 °C	% Assay	107.5	93.8	103.1
Temp. 32 °C	% Assay	107.9	93.7	103.5




Figure 1. Mannitol RT: 8.1 min in RID detector




Figure 2. Ciprofloxacin RT: 3.1 min Salbutamol RT: 5.9 mins in UV detector

Results

100% level of Standard solutions were injected to evaluate system suitability. The % RSD (< 2%) for the system suitability parameters of retention time, peak area, tailing factor (NMT 1.5) and theoretical plates (NLT 1000) was calculated and were within limits Table 1. Specificity was demonstrated by injecting a mixture of 100 ppm of Salbutamol, 4000 ppm of Ciprofloxacin and 10000 ppm of Mannitol. The resolution for Salbutamol and Ciprofloxacin is within the acceptance criteria of ($R \geq 1.5$), indicating the method was specific for the three components. Linearity was demonstrated by plotting the graph between peak areas and assay concentration; the correlation coefficient was greater than 0.99 for Salbutamol, Ciprofloxacin and Mannitol (table 1). This indicates that all three components have good linearity in the range studied.

Precision for the Assay test was checked by injecting six individual preparations of the samples, and the % RSD obtained was 0.22, 0.29 & 0.15% for Salbutamol, Ciprofloxacin, and Mannitol, respectively. And Intermediate precision was performed by testing six individual preparations on another day. The % RSD was 0.12, 0.48 and 0.29% for Salbutamol, Ciprofloxacin, and Mannitol, respectively. (Table 1). The recovery was within $\pm 10\%$ of the concentration studied, and the % RSD was within $\pm 1.0\%$. (Table 1). Indicating the method is precise and accurate.

With the increase in pH from 6.8 to 7 to 7.2 and with the variation in column temperature from 28 deg C to 32 deg C, the Assay value was similar for Salbutamol, Ciprofloxacin, and Mannitol Table 1., indicating the effect of temperature and pH within the range studied does not have a significant impact on the analytical procedure.

4. Conclusions

A simple, economical, and rapid isocratic HPLC method has been developed and validated for quantitatively estimating Salbutamol, Ciprofloxacin and Mannitol on a single HPLC column and two detectors (UV and RID). The HPLC method was validated in line with ICH guidelines. The results show that the developed method is sensitive, linear, precise, accurate and robust. The developed method can be used for quantitative estimation of Salbutamol, Ciprofloxacin and Mannitol, making it suitable for QC release and stability studies.

ACKNOWLEDGEMENTS

We express our gratitude to Mr Nilesh Dhamorikar and Qbd Labs for their support in conducting this research.

REFERENCES

- [1] Barisione, G. et al. (2010). Beta-adrenergic agonists. *Pharmaceuticals*, 3(4), 1016–1044, <https://doi.org/10.3390/ph3041016>.
- [2] Hooper, D.C. (2000). Mechanisms of Action and Resistance of Older and Newer Fluoroquinolones. *Clinical infectious diseases*, 31(Supplement-2), S24–S28, <https://doi.org/10.1086/314056>.
- [3] Bilton, D. et al. (2014). Inhaled mannitol for non-cystic fibrosis bronchiectasis: A randomized, controlled trial. *Thorax*, 69(12), 1073–1079 <https://doi.org/10.1136/thoraxjnl-2014-205587>.
- [4] European Medicines Agency. (2012). Bronchitol - Summary of Product Characteristics. [Online]. Available at: https://www.ema.europa.eu/en/documents/product-information/bronchitol-epar-product-information_en.pdf [Accessed 21 August 2023]
- [5] Ambadekar, S.R. et al. (2018). Validation of Pharmaceutical (API) Bulk Drug by HPLC Methods. *IOSR-JAC*, 11(2), 01-20. <https://doi.org/10.9790/5736-1102020120>.
- [6] Yogesh, S. et al. (2011). Method development and validation of salbutamol sulphate and its related impurities by RP-HPLC. *Int. J. Pharma Sci*, 3(1), 1178-1197.
- [7] Momin, M. et al. (2013). Development and validation of stability indicating assay method of Salbutamol sulphate metered dose inhaler by HPLC. *Int. J. Pharm. Phytopharmacol. Res.*, 2(6), 439-448.
- [8] Sowjanya, G. et al. (2018). Development And Validation Of A New RP-HPLC Method For The Simultaneous Determination Of Albuterol Sulphate And Ipratropium Bromide In Nasal Inhalations. *Int. Res. J. Pharm.*, 9(8), 63-70, <https://doi.org/10.7897/2230-8407.098166>.
- [9] Gandhi, S.V. et al. (2015). Development And Validation Of Stability Indicating RP-HPLC Method For Simultaneous

- Estimation Of Beclomethasone Dipropionate And Salbutamol Sulphate. *Int. J. Pharm. Pharm.*, 7(6), 252-257.
- [10] McShane, P.J. et al. (2018). Ciprofloxacin Dry Powder For Inhalation (Ciprofloxacin DPI): Technical Design And Features Of An Efficient Drug-Device Combination. *Pulm. Pharmacol.*, 50, 72-79. <https://doi.org/10.1016/j.pupt.2018.03.005>.
- [11] Patel, K.B. et al. (2014). Stability Indicating HPLC Method For Simultaneous Estimation Of Ciprofloxacin And Phenylephrine In Pharmaceutical Dosage Form. *Pharmacophore.*, 5(2), 262-272.
- [12] Alapati, V.R. et al. (2014). Validated Stability Indicating Liquid Chromatographic Method For Quantification Of Ciprofloxacin Hcl, Its Related Substance And Tinidazole In Tablet Dosage Form. *Int. J. Pharm. Pharm. Sci.*, 6(5), 611-615.
- [13] Aksoy, B. et al. (2007). Development And Validation Of A Stability-Indicating Hplc Method For Determination Of Ciprofloxacin Hydrochloride And Its Related Compounds In Film-Coated Tablets. *Chromatographia*, 66(S1), 57- 63. <https://doi:10.1365/s10337-007-0287-6>.
- [14] Bushra, M. et al. (2013). Study of forced degradation of ciprofloxacin HCl indicating stability using RP-HPLC method. *Der Pharma Chem.*, 5(6), 132-137, <http://derpharmachemica.com/archive.html>.
- [15] Kaialy, W. et al. (2013). Towards a More Desirable Dry Powder Inhaler Formulation: Large Spray-Dried Mannitol Microspheres Outperform Small Microspheres. *Pharm Res* 31, 60–76, <https://doi.org/10.1007/s11095-013-1132-2>.
- [16] Samarco, E.C. and Parente, E.S. (1982). Automated high pressure liquid chromatographic system for determination of mannitol, sorbitol, and xylitol in chewing gums and confections. *Journal of Association of Official Analytical Chemists*, 65(1), 76–78, <https://doi.org/10.1093/jaoac/65.1.76>.
- [17] Hadjikinova, R. et al. (2017). Development and validation of HPLC-RID method for determination of sugars and polyols. *Journal of pharmaceutical sciences and research*, 9(8), 1263–1269.
- [18] Risley, D.S., Yang, W.Q. and Peterson, J.A. (2006). Analysis of mannitol in pharmaceutical formulations using hydrophilic interaction liquid chromatography with evaporative light-scattering detection. *Journal of separation science*, 29(2), 256–264.
- [19] Sławińska, A., Jabłońska-Ryś, E. and Stachniuk, A. (2021). High-Performance Liquid Chromatography Determination of Free Sugars and Mannitol in Mushrooms Using Corona Charged Aerosol Detection. *Food analytical methods*, 14(2), pp.209–216.
- [20] ICH Q2B (R1) Validation of Analytical Procedures. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-2-r1-validation-analytical-procedures-text-methodology-step-5_en.pdf.
- [21] ICH Q1 B Photostability testing of new Drug substances and new drug products.
- [22] Shodex Technical notebook 2: Shodex NH2P-50 series columns. Analysis of saccharides in food industry.